Olympus Corporation (OCPNF)
OTCMKTS
· Delayed Price · Currency is USD
12.92
+0.26 (2.08%)
At close: May 20, 2025
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Total Medical Solutions Division | 996.80B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Solutions Division Growth | 7.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division | 636.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division Growth | 8.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division | 360.66B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Growth | 6.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Post-FY2024 Reporting) | 530.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Post-FY2024 Reporting) Growth | -70.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Total Medical Solutions Division Operating Profit | 202.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Solutions Division Operating Profit Growth | 110.82% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division Operating Profit | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Scientific Solutions Division Operating Profit Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Pre-FY2025 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Division Operating Profit | -39.92B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Division Operating Profit Growth | -10.39% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division Operating Profit | 141.40B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endoscopic Solutions Division Operating Profit Growth | 35.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Operating Profit | 61.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Operating Profit Growth | -825.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Post-FY2024 Reporting) | -473.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Post-FY2024 Reporting) Growth | 64.81% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Japan | 110.53B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Japan Growth | -5.77% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 413.90B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | 17.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 254.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | 7.54% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Pre-FY2020 Reporting) | 189.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Pre-FY2020 Reporting) Growth | -2.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Countries | 28.84B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Countries Growth | 10.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 95.74B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | -9.97% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Post-FY2019 Reporting) | 93.71B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Post-FY2019 Reporting) Growth | 6.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2013 - 2020 |
| Company's Total Revenue Growth Rate After FX Adjustment | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment | 4.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment | 3.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment | 3.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment | 5.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ESD - Medical Service Revenue Growth Rate After FX Adjustment | 5.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment | 2.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Urology Revenue Growth Rate After FX Adjustment | 6.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Respiratory Revenue Growth Rate After FX Adjustment | 10.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment | -7.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|